Edgen Stock·Dec 12 2025, 00:57Back
Back
HanchorBio To Present Key HCB101 Cancer Data
Edgen Stock·Dec 12 2025, 00:57
[1] IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uveal Melanoma - BioSpace[2] Astellas to Present New Clinical Data Across Its Gastrointestinal Cancers Portfolio at 2026 ASCO GI Cancers Symposium - BioSpace[3] Ensoma Announces Clearance of U.K. Clinical Trial Authorization Application for EN-374, First In Vivo HSC-Directed Gene Insertion Therapy - BioSpace
Features
Resources
© 2026 Finture Development Limited. All rights reserved